BG
ENTA icon

Bollard Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Bollard Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-383
Closed -$27K – 322
2022
Q1 		$27K Hold
383
– – ﹤0.01% 376
2021
Q4 		$29K Hold
383
– – ﹤0.01% 379
2021
Q3 		$22K Hold
383
– – ﹤0.01% 387
2021
Q2 		$17K Hold
383
– – ﹤0.01% 396
2021
Q1 		$19K Hold
383
– – ﹤0.01% 396
2020
Q4 		$16K Hold
383
– – ﹤0.01% 395
2020
Q3 		$18K Sell
383
-1,208
-76% -$58.5K ﹤0.01% 390
2020
Q2 		$80K Buy
+1,591
New +$82.3K ﹤0.01% 282

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bollard Group's ENTA Position: Q2 2022 in Review

Bollard Group sold out of Enanta Pharmaceuticals (ENTA) in Q2 2022, closing a stake of 383 shares — an estimated $27K sold.

Bollard Group first reported a position in ENTA in Q2 2020 and held it in 8 quarters. The position peaked at $80K in Q2 2020. 154 funds tracked by Wall St. Rank hold ENTA as of Q2 2022.

  • Bollard Group reported no remaining Enanta Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 383 Enanta Pharmaceuticals shares in Q2 2022, an estimated $27K.
  • Bollard Group first reported a position in Enanta Pharmaceuticals in Q2 2020 and held it in 8 quarters.
  • Bollard Group's Enanta Pharmaceuticals position peaked at $80K in Q2 2020.
  • 154 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.